Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement.
about
Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enoughCIViC databaseMechanism of c-MET in Non-small Cell Lung Cancer and Its Treatment and TestingExtraordinary response to crizotinib in a woman with squamous cell lung cancer after two courses of failed chemotherapy.Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study.Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary.Targeting MET Amplification as a New Oncogenic Driver.ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.MET/HGF pathway activation as a paradigm of resistance to targeted therapies.Targeting the MET pathway for potential treatment of NSCLC.Efficacy of crizotinib inhibiting specific molecular pathways in non-small-cell lung carcinoma.Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non-Small Cell Lung Cancer Tissues from Patients Treated with CrizotinibMetastatic spread of solid subtype lung adenocarcinoma to the small intestine with anemia and melena: A case report.Emerging targeted therapies in non-small cell lung cancer.MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.Development of crizotinib, a rationally designed tyrosine kinase inhibitor for non-small cell lung cancer.The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer.miR-144-3p exerts anti-tumor effects in glioblastoma by targeting c-Met.Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: implications for MET targeting in oncology.Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification.Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies.Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients.Copy number gain of PIK3CA and MET is associated with poor prognosis in head and neck squamous cell carcinoma.
P2860
Q26799467-C00A493D-B7ED-4200-BD2F-D6D6EBC29376Q27612411-08FEAF54-A25E-4862-BEE2-7F21993BFAE8Q28077785-55428859-5EC1-435B-8FD0-51DB8DBFB184Q33637295-AB825660-07F5-45A2-BB5E-4DC6394568DAQ33688612-213C5B9A-17A1-4D76-8E8E-9E43DB70CB82Q34181172-098D83D6-2EB2-4D6F-B086-43223A163389Q34309927-53C5D061-92C0-4BDF-9EA6-5589E5C54210Q34431889-61501EF5-F84E-4BFB-AF18-5F3C3407D450Q37597850-9C222E89-7743-4CA6-B750-3C4BB24C7FA5Q38297235-714F197F-2CFA-4319-A7C1-666A2DC3774BQ38386866-1425101A-2C33-4FDC-9212-3C71C6E27136Q38567805-6D266F0A-03FB-4B72-A12D-088D29E750FAQ38611487-81918E91-74CB-43F2-A784-A89574217DF2Q38653045-DE058D51-93B0-494E-806E-8D22838312ACQ38675350-4F378698-81F3-4C88-81F9-C6BD5C8E57E8Q38792120-60E837EC-899B-4051-B554-AE714552962CQ38824065-434B1605-AED9-4552-917A-02DEC4B10F81Q38845681-DC556D1E-04F5-417D-BC5A-4DE3A1E86532Q39027803-B4764386-8D90-4C90-94A8-EE833326579FQ41412426-F9D8443D-7668-4C2D-89BF-990653BE57D2Q43901317-21C13267-4D5C-4ABB-A7F4-37E01D22FA11Q47127403-4ACDE6CD-CC91-434B-AF6A-9191008B308BQ53187961-5D18E56A-E193-4230-955F-6C9DB33DDCCF
P2860
Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Major partial response to criz ...... absence of ALK rearrangement.
@ast
Major partial response to criz ...... absence of ALK rearrangement.
@en
Major partial response to criz ...... absence of ALK rearrangement.
@nl
type
label
Major partial response to criz ...... absence of ALK rearrangement.
@ast
Major partial response to criz ...... absence of ALK rearrangement.
@en
Major partial response to criz ...... absence of ALK rearrangement.
@nl
prefLabel
Major partial response to criz ...... absence of ALK rearrangement.
@ast
Major partial response to criz ...... absence of ALK rearrangement.
@en
Major partial response to criz ...... absence of ALK rearrangement.
@nl
P2093
P1433
P1476
Major partial response to criz ...... absence of ALK rearrangement.
@en
P2093
Andrea Kohanka
Diana Brauswetter
Edit Varkondi
Ferenc Pinter
Helga Barti-Juhasz
Istvan Petak
Julia Schönleber
Laszlo Kopper
Laszlo Urban
Mihaly Kollar
P304
P356
10.1016/J.LUNGCAN.2013.10.006
P577
2014-01-01T00:00:00Z